AMO Pharma Launches Largest-Ever Clinical Trial for Rare Heart Condition ARVC with GSK3β Inhibitor AMO-02
核心洞察
AMO Pharma (搜索) has initiated the TaRGET Phase 2 trial, the largest clinical study ever conducted for arrhythmogenic right ventricular cardiomyopathy (搜索) (ARVC (搜索)), enrolling 120 patients across 17 Canadian sites.
The investigational therapy AMO-02 targets glycogen synthase kinase-3 beta (搜索) (GSK3β (搜索)), addressing the underlying disease biology of ARVC (搜索) caused by genetic mutations in desmosomal genes.
Preclinical studies demonstrated that AMO-02 reduced arrhythmias and cardiomyopathy while preventing disease progression and reversing existing features in mouse models with human ARVC (搜索) mutations.
AMO Pharma (搜索) Limited has launched the TaRGET Phase 2 proof-of-concept clinical trial, marking the largest therapeutic study ever conducted for arrhythmogenic right ventricular cardiomyopathy (搜索) (ARVC (搜索)). The randomized, double-blind, placebo-controlled trial is evaluating AMO-02, an investigational GSK3β (搜索) inhibitor, across 17 sites in Canada with 120 patients expected to enroll.
The clinical-stage specialty biopharmaceutical company announced a license agreement with the Population Health Research Institute (PHRI (搜索)), a joint research institute of McMaster University and Hamilton Health Sciences (搜索), and Venca Research Inc (搜索). to support the development, potential manufacturing, and commercialization of AMO-02 for ARVC (搜索) treatment.
Targeting the Root Cause of ARVC
ARVC (搜索) is a rare, inherited cardiomyopathy that can lead to heart failure (搜索), malignant ventricular arrhythmias (搜索), and sudden cardiac death (搜索). The condition is most often caused by genetic mutations in desmosomal genes that trigger abnormal activation of the enzyme GSK3β (搜索) in cardiac cells. ARVC represents a subtype of arrhythmogenic cardiomyopathy (搜索) (ACM), a broader condition that can also affect the left ventricle or both ventricles.
"AMO Pharma (搜索) is committed to advancing and supporting research that can lead to new first-in-class disease-modifying therapies for serious, life-threatening conditions such as ARVC (搜索)," said Mike Snape, Chief Scientific Officer at AMO Pharma. "The recent publication in JACC: Basic to Translational Science reinforces the growing body of evidence supporting glycogen synthase kinase-3 beta (搜索) (GSK3β (搜索)) inhibition as a potential treatment strategy for ARVC and the broader ACM spectrum, which is central to our approach with AMO-02."
Promising Preclinical Results
The therapeutic approach is supported by compelling preclinical data demonstrating AMO-02's potential to address the underlying disease mechanisms. Dr. Jason Roberts, principal investigator of the study and PHRI (搜索) scientist, explained the preclinical findings: "In preclinical studies, insertion of human ARVC (搜索) gene mutations into mice reproduced all the major signs and symptoms of the disease. When studied in these models, AMO-02 reduced arrhythmias and cardiomyopathy, and both prevented progression and reversed existing disease features."
These preclinical results strongly support AMO-02's potential to address the underlying drivers of ARVC (搜索) and offer a much-needed therapeutic option for patients with this rare condition.
Trial Design and Endpoints
The TaRGET study is evaluating AMO-02 in patients with genotype-positive ARVC (搜索). The primary endpoint measures the change from baseline in mean premature ventricular contractions per 24 hours, assessed through seven-day Holter monitoring compared to placebo at six months of treatment.
Secondary endpoints include right ventricular strain on echocardiography, frequency of implantable cardioverter-defibrillator therapies, and episodes of sustained ventricular tachycardia. Under the license agreement terms, AMO Pharma (搜索) will collaborate closely with PHRI (搜索) on regulatory interactions and study oversight.
Timeline and Broader Pipeline
First data from the TaRGET trial are expected in the second quarter of 2027. Beyond ARVC (搜索), AMO Pharma (搜索) is developing AMO-02 for myotonic dystrophy type 1 (搜索) (DM1), while advancing other investigational therapies including AMO-01 for Phelan-McDermid syndrome (搜索) and AMO-04 for Rett syndrome (搜索) and related disorders.
Snape emphasized the collaboration's significance: "We look forward to partnering with PHRI (搜索) to advance this landmark precision cardiology program, which has the potential to change the treatment landscape for patients living with ARVC (搜索) by targeting the underlying disease biology. This collaboration builds on extensive prior research highlighting AMO-02's mechanism of action indicating the potential to correct abnormal GSK3β (搜索) activity in the heart, and its established unique profile as a safe and well-tolerated GSK3β inhibitor."